- Home
- LUCY vs SILO Comparison
LUCY vs SILO Comparison
Compare LUCY & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCY
- SILO
- Stock Information
- Founded
- LUCY 2017
- SILO 2010
- Country
- LUCY United States
- SILO United States
- Employees
- LUCY N/A
- SILO N/A
- Industry
- LUCY Ophthalmic Goods
- SILO Apparel
- Sector
- LUCY Health Care
- SILO Consumer Discretionary
- Exchange
- LUCY Nasdaq
- SILO Nasdaq
- Market Cap
- LUCY 8.7M
- SILO 7.3M
- IPO Year
- LUCY 2022
- SILO N/A
- Fundamental
- Price
- LUCY $1.97
- SILO $0.66
- Analyst Decision
- LUCY
- SILO
- Analyst Count
- LUCY 0
- SILO 0
- Target Price
- LUCY N/A
- SILO N/A
- AVG Volume (30 Days)
- LUCY 634.0K
- SILO 3.1M
- Earning Date
- LUCY 11-11-2025
- SILO 11-11-2025
- Dividend Yield
- LUCY N/A
- SILO N/A
- EPS Growth
- LUCY N/A
- SILO N/A
- EPS
- LUCY N/A
- SILO N/A
- Revenue
- LUCY $1,978,018.00
- SILO $72,102.00
- Revenue This Year
- LUCY $149.32
- SILO $1.86
- Revenue Next Year
- LUCY $400.00
- SILO N/A
- P/E Ratio
- LUCY N/A
- SILO N/A
- Revenue Growth
- LUCY 29.30
- SILO N/A
- 52 Week Low
- LUCY $1.57
- SILO $0.41
- 52 Week High
- LUCY $10.40
- SILO $3.37
- Technical
- Relative Strength Index (RSI)
- LUCY 49.26
- SILO 45.05
- Support Level
- LUCY $1.94
- SILO $0.66
- Resistance Level
- LUCY $2.08
- SILO $0.72
- Average True Range (ATR)
- LUCY 0.12
- SILO 0.07
- MACD
- LUCY 0.00
- SILO -0.01
- Stochastic Oscillator
- LUCY 20.85
- SILO 4.33
About LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.